<DOC>
	<DOCNO>NCT02595489</DOCNO>
	<brief_summary>In pilot study , investigator assess safety two high-dose regimen oral vitamin D supplementation measure effect vitamin D supplementation marker oxidative stress inflammation blood brain study participant , , take vitamin D supplement . The goal study establish research measure ( i.e . biomarkers ) optimal dose vitamin D supplementation boys X-linked adrenoleukodystrophy ( ALD ) genotype .</brief_summary>
	<brief_title>A Pilot Study Vitamin D Boys With X-linked Adrenoleukodystrophy</brief_title>
	<detailed_description>Prior research suggest high vitamin D level blood associate reduce brain inflammation among individual multiple sclerosis , disease similar cerebral demyelinating form ALD . However , serious side effect ( e.g . hypercalcemia , kidney stone ) occur vitamin D level get high . The current study design establish safe dose vitamin D boys ALD . Although dos choose study expect safe , investigator monitor participant early sign vitamin D-related toxicity . The investigator also examine whether vitamin D supplementation affect marker oxidative stress inflammation blood brain ALD boys . The study require participant agree least one year participation . Participants ask take vitamin D supplement every day , submit blood analysis every 3 month first year , visit study center ( Stanford University University Minnesota ) every 6 month throughout period study . Participants take 2,000 international unit ( IU ) vitamin D3 daily 6 month period , follow increase 4,000 IU daily least 6 month thereafter . The vitamin D supplement provide study . In keep current standard care ALD boys age 3-12 year , participant need visit study site every six month order complete clinic visit MRI brain gadolinium . As part study , however , participant ' need submit blood work every 3 month first year order study investigator ensure participant ' calcium vitamin D level safe range study effect vitamin D marker blood . The MRI protocol first year also include one additional sequence ( magnetic resonance spectroscopy ) order measure brain metabolite . The data generate study intend , part , help design future , large-scale clinical trial determine whether vitamin D supplementation capable reduce risk develop cerebral demyelinate form ALD .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Criteria enrollment screening : 1 . Molecular confirmation Xlinked ALD ( VLCFA elevation &amp; ABCD1 mutation ) 2 . Male 3 . Age 3yrs 12yrs screening Criteria assignment drug : 1 . Plasma 25hydroxy vitamin D level â‰¤ 35ng/ml past 90 day 2 . MRI brain past 30 day negative evidence active cerebral demyelination history liver kidney disease history nephrolithiasis history hyperthyroidism history ulcerative colitis , Crohn 's disease , celiac disease take medication interfere gastrointestinal absorption contraindication inability complete MRI every 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukodystrophy</keyword>
	<keyword>ABCD1</keyword>
	<keyword>Demyelination</keyword>
	<keyword>Inflammation</keyword>
	<keyword>ALD</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>X- link</keyword>
	<keyword>Adrenoleukodystrophy</keyword>
</DOC>